145 related articles for article (PubMed ID: 34054700)
1. Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Chen S; Liang T; Xue T; Xue S; Xue Q
Front Neurol; 2021; 12():658123. PubMed ID: 34054700
[No Abstract] [Full Text] [Related]
2. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
Reilmann R; McGarry A; Grachev ID; Savola JM; Borowsky B; Eyal E; Gross N; Langbehn D; Schubert R; Wickenberg AT; Papapetropoulos S; Hayden M; Squitieri F; Kieburtz K; Landwehrmeyer GB; ;
Lancet Neurol; 2019 Feb; 18(2):165-176. PubMed ID: 30563778
[TBL] [Abstract][Full Text] [Related]
3. The Efficacy and Safety of Pridopidine on Treatment of Patients with Huntington's Disease: A Systematic Review and Meta-Analysis.
Asla MM; Nawar AA; Abdelsalam A; Elsayed E; Rizk MA; Hussein MA; Kamel WA
Mov Disord Clin Pract; 2022 Jan; 9(1):20-30. PubMed ID: 35005061
[TBL] [Abstract][Full Text] [Related]
4. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J;
Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
[TBL] [Abstract][Full Text] [Related]
5. Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.
McGarry A; Kieburtz K; Abler V; Grachev ID; Gandhi S; Auinger P; Papapetropoulos S; Hayden M
J Huntingtons Dis; 2017; 6(3):189-199. PubMed ID: 28826192
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
Huntington Study Group HART Investigators
Mov Disord; 2013 Sep; 28(10):1407-15. PubMed ID: 23450660
[TBL] [Abstract][Full Text] [Related]
7. Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose.
Darpo B; Geva M; Ferber G; Goldberg YP; Cruz-Herranz A; Mehra M; Kovacs R; Hayden MR
Neurol Ther; 2023 Apr; 12(2):597-617. PubMed ID: 36811812
[TBL] [Abstract][Full Text] [Related]
8. Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.
Waters S; Tedroff J; Ponten H; Klamer D; Sonesson C; Waters N
J Huntingtons Dis; 2018; 7(1):1-16. PubMed ID: 29480206
[TBL] [Abstract][Full Text] [Related]
9. Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.
McGarry A; Auinger P; Kieburtz K; Geva M; Mehra M; Abler V; Grachev ID; Gordon MF; Savola JM; Gandhi S; Papapetropoulos S; Hayden M
J Huntingtons Dis; 2020; 9(2):173-184. PubMed ID: 32508327
[TBL] [Abstract][Full Text] [Related]
10. Pridopidine for the treatment of Huntington's disease.
Shannon KM
Expert Opin Investig Drugs; 2016; 25(4):485-92. PubMed ID: 26881734
[TBL] [Abstract][Full Text] [Related]
11. Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study.
McGarry A; Leinonen M; Kieburtz K; Geva M; Olanow CW; Hayden M
J Huntingtons Dis; 2020; 9(4):371-380. PubMed ID: 33164941
[TBL] [Abstract][Full Text] [Related]
12. Pridopidine Reverses Phencyclidine-Induced Memory Impairment.
Sahlholm K; Valle-León M; Fernández-Dueñas V; Ciruela F
Front Pharmacol; 2018; 9():338. PubMed ID: 29692729
[TBL] [Abstract][Full Text] [Related]
13. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
14. The most appropriate primary outcomes to design clinical trials on Huntington's disease: meta-analyses of cohort studies and randomized placebo-controlled trials.
Salem L; Saleh N; Youssov K; Olivier A; Charles P; Scherer C; Verny C; Bachoud-Lévi AC; Maison P
Fundam Clin Pharmacol; 2014 Dec; 28(6):700-10. PubMed ID: 24702447
[TBL] [Abstract][Full Text] [Related]
15. The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease.
Rabinovich-Guilatt L; Siegler KE; Schultz A; Halabi A; Rembratt A; Spiegelstein O
Br J Clin Pharmacol; 2016 Feb; 81(2):246-55. PubMed ID: 26407011
[TBL] [Abstract][Full Text] [Related]
16. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease.
Reilmann R; Bohlen S; Klopstock T; Bender A; Weindl A; Saemann P; Auer DP; Ringelstein EB; Lange HW
Mov Disord; 2010 Oct; 25(13):2195-202. PubMed ID: 20645403
[TBL] [Abstract][Full Text] [Related]
17. Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations.
Mestre TA; Forjaz MJ; Mahlknecht P; Cardoso F; Ferreira JJ; Reilmann R; Sampaio C; Goetz CG; Cubo E; Martinez-Martin P; Stebbins GT;
Mov Disord Clin Pract; 2018; 5(2):111-117. PubMed ID: 30363393
[TBL] [Abstract][Full Text] [Related]
18. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).
Gordon M; Naidoo K; Akobeng AK; Thomas AG
Evid Based Child Health; 2013 Jan; 8(1):57-109. PubMed ID: 23878124
[TBL] [Abstract][Full Text] [Related]
19. Pridopidine in the treatment of Huntington's disease.
Jabłońska M; Grzelakowska K; Wiśniewski B; Mazur E; Leis K; Gałązka P
Rev Neurosci; 2020 May; 31(4):441-451. PubMed ID: 32083454
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]